Erina Co.

Minato-ku, Japan

Erina Co.

Minato-ku, Japan
SEARCH FILTERS
Time filter
Source Type

Patent
Erina Co. and Kands R&D Corporation | Date: 2014-10-18

The present invention provides a method for suppressing and relieving itching and inflammation, by administering to a host in need of such treatment an effective amount of the pharmaceutical composition containing highly lipophilic polyalkoxyflavonoid. The pharmaceutical composition and functional food of the present invention for suppressing and relieving itching and inflammation contain highly lipophilic polyalkoxyflavonoid extracted from squeezed juice of a whole portion of a citrus fruit (inclusive of pericarp thereof). Furthermore, the functional food of the present invention contains it.


Patent
Erina Co. and Kands R&D Corporation | Date: 2012-02-10

The present invention provides a method for suppressing and relieving itching and inflammation, by administering to a host in need of such treatment an effective amount of the pharmaceutical composition containing highly lipophilic polyalkoxyflavonoid. The pharmaceutical composition and functional food of the present invention for suppressing and relieving itching and inflammation contain highly lipophilic polyalkoxyflavonoid extracted from squeezed juice of a whole portion of a citrus fruit (inclusive of pericarp thereof). Furthermore, the functional food of the present invention contains it.


Lee Y.-S.,Chubu University | Cha B.-Y.,Chubu University | Choi S.-S.,Chubu University | Choi B.-K.,Chubu University | And 5 more authors.
Journal of Nutritional Biochemistry | Year: 2013

Nobiletin (NOB) is a polymethoxylated flavone present in citrus fruits and has been reported to have antitumor and anti-inflammatory effects. However, little is known about the effects of NOB on obesity and insulin resistance. In this study, we examined the effects of NOB on obesity and insulin resistance, and the underlying mechanisms, in high-fat diet (HFD)-induced obese mice. Obese mice were fed a HFD for 8. weeks and then treated without (HFD control group) or with NOB at 10 or 100. mg/kg. NOB decreased body weight gain, white adipose tissue (WAT) weight and plasma triglyceride. Plasma glucose levels tended to decrease compared with the HFD group and improved plasma adiponectin levels and glucose tolerance. Furthermore, NOB altered the expression levels of several lipid metabolism-related and adipokine genes. NOB increased the mRNA expression of peroxisome proliferator-activated receptor (PPAR)-γ, sterol regulatory element-binding protein-1c, fatty acid synthase, stearoyl-CoA desaturase-1, PPAR-α, carnitine palmitoyltransferase-1, uncoupling protein-2 and adiponectin, and decreased the mRNA expression of tumor necrosis factor-α and monocyte chemoattractant protein-1 in WAT. NOB also up-regulated glucose transporter-4 protein expression and Akt phosphorylation and suppressed IκBα degradation in WAT. Taken together, these results suggest that NOB improves adiposity, dyslipidemia, hyperglycemia and insulin resistance. These effects may be elicited by regulating the expression of lipid metabolism-related and adipokine genes, and by regulating the expression of inflammatory makers and activity of the insulin signaling pathway. © 2013 Elsevier Inc.


Lee Y.-S.,Chubu University | Cha B.-Y.,Chubu University | Saito K.,Chubu University | Yamakawa H.,Chubu University | And 7 more authors.
Biochemical Pharmacology | Year: 2010

Nobiletin is a polymethoxylated flavone found in certain citrus fruits that exhibits various pharmacological effects including anti-inflammatory, antitumor and neuroprotective properties. The present study investigated the effects of nobiletin on insulin sensitivity in obese diabetic ob/. ob mice, and the possible mechanisms involved. The ob/. ob mice were treated with nobiletin (200. mg/kg) for 5 weeks. Nobiletin significantly improved the plasma glucose levels, homeostasis model assessment index, glucose tolerance in an oral glucose tolerance test and plasma adiponectin levels. In white adipose tissue (WAT), nobiletin significantly decreased the mRNA expression levels of inflammatory adipokines such as interleukin (IL)-6 and monocyte chemoattractant protein (MCP)-1 and increased the mRNA expression levels of adiponectin, peroxisome proliferator-activated receptor (PPAR)-γ and its target genes. At the same time, nobiletin increased the glucose transporter (Glut) 4 expression levels in the whole plasma membrane, and Glut1 and phospho-Akt expression in the whole cell lysates in WAT and muscle. Nobiletin also increased Glut4 protein expression level in the whole cell lysates of the muscle. Taken together, the present results suggest that nobiletin improved the hyperglycemia and insulin resistance in obese diabetic ob/. ob mice by regulating expression of Glut1 and Glut4 in WAT and muscle, and expression of adipokines in WAT. © 2010 Elsevier Inc.


Choi S.-S.,Chubu University | Cha B.-Y.,Chubu University | Iida K.,Chubu University | Lee Y.-S.,Chubu University | And 5 more authors.
Biochemical Pharmacology | Year: 2011

The nuclear receptor peroxisome proliferator-activated receptor (PPAR) γ plays an important role in adipocyte differentiation. Its ligands, including thiazolidinediones, improve insulin sensitivity in type 2 diabetes. We investigated the effects of artepillin C, an ingredient of Baccharis dracunculifolia, on adipogenesis and glucose uptake using 3T3-L1 cells. In PPARγ ligand-binding assays, artepillin C exhibited binding affinity toward PPARγ. Artepillin C dose-dependently enhanced adipocyte differentiation of 3T3-L1 cells. As a result of the artepillin C-induced adipocyte differentiation, the gene expression of PPARγ and its target genes, such as aP2, adiponectin and glucose transporter (GLUT) 4, was increased. These increases were abolished by cotreatment with GW9662, a PPARγ antagonist. In mature 3T3-L1 adipocytes, artepillin C significantly enhanced the basal and insulin-stimulated glucose uptake. These effects were decreased by cotreatment with a PI3K inhibitor. Although artepillin C had no effects on the insulin signaling cascade, artepillin C enhanced the expression and plasma membrane translocation of GLUT1 and GLUT4 in mature adipocytes. In conclusion, these findings suggest that artepillin C promotes adipocyte differentiation and glucose uptake in part by direct binding to PPARγ, which could be the basis of the pharmacological benefits of green propolis intake in reducing the risk of type 2 diabetes. © 2011 Elsevier Inc. All rights reserved.


Patent
Erina Co. Inc. | Date: 2012-03-28

Disclosed are: a method for screening a substance for treating metabolic syndrome that develops visceral obesity and abnormal lipid metabolism; and a composition for preventing and/or treating the syndrome. The screening method comprises: (1) an extraction step of extracting a total RNA fraction from a skeletal muscle collected from each of non-human mammals that constitute a test substance-administered group to which a predetermined amount of the test substance has been administered for a predetermined period and each of non-human mammals that constitute a test substance-unadministered group to which the test substance has not been administered; (2) a quantification step of quantifying the expression quantity of mRNA contained in the total RNA fraction extracted in the extraction step and encoding a sugar transporter gene by a specific method; and (3) a step of comparing and analyzing the quantity of the test substance ingested, the body weight gain, and the expression quantity of RNA encoding the sugar transporter gene during the predetermined period between the non-human mammals that constitute the test substance-administered group and the non-human mammals that constitute the test substance-unadministered group to thereby determine the effect of the test substance on the metabolic syndrome.


Provided is a composition that, even when used in a very small amount, has the effect of improving bone density and promoting bone growth, and has few side effects, and also provided are a pharmaceutical preparation for promoting bone growth, functional food product, and health food product containing the composition as an active ingredient. The composition can be obtained from any plant part selected from the group consisting of the bud, leaf, bark or wood of a plant belonging to the family Magnoliaceae. The composition comprises at least one selected from the group consisting of fargesin and physiologically acceptable salts, hydrates, and glycosides thereof. The pharmaceutical preparation, functional food product, and health food product comprising this composition as an active ingredient sufficiently improve bone density and promote bone growth, even when used in small amounts, and therefore realize preventive and/or therapeutic effects against bone disease etc. such as osteoporosis.


Agents or pharmaceutical compositions for promoting osteoblast differentiation include purified auraptene or coumarin analogs thereof represented by the following formula 1: wherein R1 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, or a carboxyethyl; R2 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl, a carboxyethyl or a coumarinyl; R3 represents a hydrogen, a hydroxy, a methoxy, a methyl, an ethyl, a propyl, a carboxyl, a carboxymethyl or a carboxyethyl; and R4 represents a hydrogen, a C_(1)-C_(15 )liner or branched alkyl, an alkenyl, an alkadienyl or an alkatrienyl.


A method for screening a substance for treating visceral adiposity syndrome comprises: (1) extracting a total RNA fraction from skeletal muscle collected from non-human mammals of a group to which a predetermined amount of the test substance has been administered and from non-human mammals of a group to which the test substance has not been administered; (2) quantifying the expression quantity of mRNA in the total RNA fraction extracted that encodes a glucose transporter gene by a specific method; and (3) comparing and analyzing the quantity of the test substance ingested, the body weight gain, and the expression quantity of RNA encoding the glucose transporter gene during the administration period for the non-human mammals of the test substance-administered group to these quantities for the non-human mammals that constitute the test substance-unadministered group to thereby determine the effect of the test substance on the metabolic syndrome.


The purpose of the present invention is to provide a highly safe composition that improves glucose tolerance and sugar metabolism at skeletal muscles, and a prevention/treatment drug for diabetes/metabolic syndrome containing the composition. Provided is a composition that is for improving sugar metabolism and glucose tolerance and that contains a compound represented by formula (I) derived from a plant selected from the group consisting of Rumex japonicus, R. crispus, and R. obtusifolius as the active ingredient.

Loading Erina Co. collaborators
Loading Erina Co. collaborators